shutterstock_144311362

ACO Name and Location

Loudoun Medical Group ACO LLC
224-D Cornwall St., NW
Ste 403
Leesburg, Virginia 20176

ACO Primary Contact

Primary Contact Name   Mary Beth Tamasy, CEO
Primary Contact Phone Number   (703) 737-6006
Primary Contact Email Address   mtamasy@lmgdoctors.com

Organizational Information

ACO Participants     ACO Participant in Joint Venture (Enter Y or N)
Loudoun Medical Group PC     N

  

ACO Governing Body:

 Last Name  First Name Title/Position Voting Power Membership Type ACO Participant TIN / Legal Business Name
Crowley, MD Anthony Chairman 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Calihan, MD Martha Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Kuo, MD Michael Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Hetzel, MD Robert Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Mellis, MD Michael G. Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Beloy, MD Amie Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Nekoba, MD Jeffrey Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Thompson, MD Jennnifer B. Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Rajendra, MD Rangappa Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Akhtar, MD Naumann Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Tamasy Mary Beth Voting Member 1.00 ACO Participant Representative Loudoun Medical Group ACO, LLC
Kearns Kathryn Voting Member 1.00 Medicare Beneficiary Representative N/A

Key ACO Clinical and Administrative Leadership:

Mary Beth Tamasy   ACO Executive
Anthony Crowley   Medical Director
Clara Nussbaum   Compliance Officer
 Clara Nussbaum  Quality Assurance/Improvement Officer

 

Associated Committees and Committee Leadership:

Committee Name Committee Leader Name and Position
 Quality Assurance and Improvement Committee  Anthony Crowley, MD, Chair
 Finance Committee  Robert Hetzel, MD, Chair
 Communications Committee  Linda Coleman, MD, Chair

Types of ACO participants, or combinations of participants, that formed the ACO:

  • ACO professionals in a group practice arrangement

Shared Savings and Losses

Amount of Shared Savings/Losses

  • First Agreement Period
    • Performance Year 2016, $0
    • Performance Year 2015, $0
    • Performance Year 2014, $0

Shared Savings Distribution

  • First Agreement Period
    • Performance Year 2016
      • Proportion invested in infrastructure: N/A
      • Proportion invested in redesigned care processes/resources: N/A
      • Proportion of distribution to ACO participants: N/A
    • Performance Year 2015
      • Proportion invested in infrastructure: N/A
      • Proportion invested in redesigned care processes/resources: N/A
      • Proportion of distribution to ACO participants: N/A
    • Performance Year 2014
        • Proportion invested in infrastructure: N/A
        • Proportion invested in redesigned care processes/resources: N/A
        • Proportion of distribution to ACO participants: N/A

          Quality Performance Results

          2016 Quality Performance Results:

          ACO# Measure Name Rate ACO Mean
          ACO-1 CAHPS: Getting Timely Care, Appointments, and Information 86.10 80.51
          ACO-2 CAHPS: How Well Your Providers Communicate 93.43 93.01
          ACO-3 CAHPS: Patients’ Rating of Provider 92.14 92.25
          ACO-4 CAHPS: Access to Specialists 81.66 83.49
          ACO-5 CAHPS: Health Promotion and Education 58.43 60.32
          ACO-6 CAHPS: Shared Decision Making 74.25 75.40
          ACO-7 CAHPS: Health Status/Functional Status 76.34 72.30
          ACO-34 CAHPS: Stewardship of Patient Resources 29.75 26.97
          ACO-8 Risk Standardized, All Condition Readmission 15.00 14.70
          ACO-35 Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM) 17.25 18.17
          ACO-36 All-Cause Unplanned Admissions for Patients with Diabetes 56.03 53.20
          ACO-37 All-Cause Unplanned Admissions for Patients with Heart Failure 82.63 75.23
          ACO-38 All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions 70.35 59.81
          ACO-9 Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5) 10.25 9.27
          ACO-10 Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8) 22.52 14.53
          ACO-11 Percent of PCPs who Successfully Meet Meaningful Use Requirements 74.19 82.72
          ACO-39 Documentation of Current Medications in the Medical Record 98.65 87.54
          ACO-13 Falls: Screening for Future Fall Risk 59.70 64.04
          ACO-14 Preventive Care and Screening: Influenza Immunization 70.15 68.32
          ACO-15 Pneumonia Vaccination Status for Older Adults 73.21 69.21
          ACO-16 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up 86.04 74.45
          ACO-17 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention 98.70 90.98
          ACO-18 Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan 38.19 53.63
          ACO-19 Colorectal Cancer Screening 63.53 61.52
          ACO-20 Breast Cancer Screening 58.72 67.61
          ACO-21 Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented 98.51 76.79
          ACO-42 Statin therapy for the Prevention and Treatment of Cardiovascular Disease 83.82 77.72
          ACO-27 Diabetes Mellitus: Hemoglobin A1c Poor Control 21.98 18.24
          ACO-41 Diabetes: Eye Exam 30.56 44.94
          ACO-28 Hypertension (HTN): Controlling High Blood Pressure 65.49 70.69
          ACO-30 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic 92.68 85.05
          ACO-31 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) 92.06 88.67
          ACO-33 Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%) 76.96 79.67

           

          Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

           

          Note: In the Quality Performance Results file(s) above, search for “Loudoun Medical Group ACO LLC” to view the quality performance results. This ACO can also be found by using the ACO ID A36039 in the public use files on data.cms.gov.

          Payment Rule Waivers

          • No, our ACO does not use the SNF 3-Day Rule Waiver.